[18F]3'-Deoxy-3'-Fluorothymidine-PET in NHL Patients: Whole-Body Biodistribution and Imaging of Lymphoma Manifestations—a Pilot Study
- 1 August 2004
- journal article
- research article
- Published by Mary Ann Liebert Inc in Cancer Biotherapy & Radiopharmaceuticals
- Vol. 19 (4) , 436-442
- https://doi.org/10.1089/cbr.2004.19.436
Abstract
Objective: The nucleoside 3′-deoxy-3′-fluorothymidine (alovudine) is an antiviral agent accumulating in proliferating cells. We prospectively evaluated the biodistribution of the PET tracer [18F]3′-deoxy-3′-fluorothymidine (FLT) and its value in detecting manifestations of non-Hodgkin's lymphoma (NHL). Methods: In this pilot study, 7 patients (6 male, 1 female) with indolent NHL (2), NHL in transformation (2) or aggressive NHL (3) were examined. Patients received initial staging or restaging with an interval of at least 10 weeks between therapy and positron emission tomography (PET). Mean doses of 324 ± 165 MBq FLT were injected intravenously. Static PET scans were performed 50–70 minutes after application. Maximum standardized uptake values (SUV) of organs and NHL manifestations were calculated. FLTpositive lesions were verified by biopsies (3 lesions) or aspiration smears (5 lesions in 4 patients). Results: Biodistribution: The tracer accumulated physiologically in hematopoietic marrow and in the liver. It was renally excreted. SUV of organs 1 hour after injection were: bones with hematopoietic marrow, 9.9 ± 4.7; liver, 5.2 ± 1.0; kidneys, 4.0 ± 1.7; spleen, 3.0 ± 1.2; bones without hematopoietic marrow, 1.9 ± 1.1; lungs, 0.8 ± 0.3. NHL manifestations: In 7 patients, diagnosis was verified as true positive by histology/cytology. Maximum lymphoma SUV of FLT positive lesions were 6 for the indolent group and 8–11 for lymphoma in transformation. In the aggressive group, SUV were 6, 14, and 17. The low SUV in this group was found in a highly proliferate large-cell anaplastic lymphoma combined with marked sclerosis of 30%. Conclusions: In this pilot study, FLT-PET was suitable in the imaging of NHL manifestations. In NHL with normal cellularity, FLT accumulated more intensely in aggressive NHL and NHL in transformation than in indolent NHL. Bones with hematopoietic marrow and the liver were the organs with the highest physiological uptake.Keywords
This publication has 10 references indexed in Scilit:
- Evaluation of pyrimidine metabolising enzymes and in vitro uptake of 3'-[18F]fluoro-3'-deoxythymidine ([18F]FLT) in pancreatic cancer cell linesEuropean Journal of Nuclear Medicine and Molecular Imaging, 2002
- 2‐(fluorine‐18)fluoro‐2‐deoxy‐D‐glucose positron emission tomography in the detection and staging of malignant lymphomaCancer, 2001
- Simplified Labeling Approach for Synthesizing 3′-Deoxy-3′-[18F]fluorothymidine ([18F]FLT)Journal of Radioanalytical and Nuclear Chemistry, 2000
- Imaging proliferation in vivo with [F-18]FLT and positron emission tomographyNature Medicine, 1998
- Relationship Between Plasma Concentrations Of 3'-Deoxy-3'-Fluorothymidine (Alovudine) And Antiretroviral Activity In Two Concentration-Controlled TrialsThe Journal of Infectious Diseases, 1994
- Improved iterative image reconstruction using variable projection binning and abbreviated convolutionEuropean Journal of Nuclear Medicine and Molecular Imaging, 1994
- Tumor diagnosis by pet: potential of seven tracers examined in five experimental tumors including an artificial metastasis modelInternational Journal of Radiation Applications and Instrumentation. Part B. Nuclear Medicine and Biology, 1992
- Comparisons of anti-human immunodeficiency virus activities, cellular transport, and plasma and intracellular pharmacokinetics of 3'-fluoro-3'-deoxythymidine and 3'-azido-3'-deoxythymidineAntimicrobial Agents and Chemotherapy, 1992
- Regulation of human thymidine kinase during the cell cycle.Journal of Biological Chemistry, 1988